This seems like a good add for INGN:
>>AUSTIN, Texas, Feb. 20 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN - news) announced today that Max W. Talbott, Ph.D. has joined the company as Senior Vice President, Worldwide Commercial Development. Dr. Talbott brings twenty-eight years of regulatory affairs experience in the pharmaceutical industry to Introgen, and over five years of experience with the U.S. Food and Drug Administration (FDA), where he attained the position of Acting Division Director and received the FDA Commendable Service Award.
David G. Nance, Introgen's president and CEO commented, ``Dr. Talbott's record of new drug registration and successful market launch of important pharmaceutical products is formidable. I am delighted that Max has joined Introgen to help move INGN 201 from the final stages of development to the market. Dr. Talbott's experience with INGN 201 dates back over six years, where as Senior Vice President of Regulatory Affairs at Rhone-Poulenc Rorer and Aventis, he led the strategic development and registration plans for INGN 201. Dr. Talbott knows our drug intimately, understands the successful regulatory submission process, is adept at label claims positioning, and is experienced in market launch activities. The addition of Dr. Talbott to our senior staff is a good complement to the accomplished drug development team already in place.''
Prior to joining Introgen, Dr. Talbott held the title of Senior Vice President, Worldwide Regulatory Affairs and Pharmacovigilance at Bristol-Myers Squibb Pharma Company and DuPont Pharmaceuticals Company. He held similar titles at Aventis Pharmaceuticals and Rhone-Poulenc Rorer Pharmaceuticals. At Eli Lilly & Company, Dr. Talbott directed worldwide regulatory operations and managed hundreds of registration submissions. Dr. Talbott served as an Acting Division Director at the FDA from 1980 until 1982. Dr. Talbott began his career at Warner-Lambert Research Institute. Dr. Talbott received his Ph.D. in Immunology and Pharmacology from Rutgers in 1976, and his M.A. in Physiology and B.S. in Biology from Ball State. Dr. Talbott has served on the editorial board of The Drug Information Journal and has published extensively in the areas of regulatory affairs, pharmaceutical public policy, immunology and pharmacology.
Dr. Talbott has led worldwide regulatory efforts for the development, registration and launch of numerous pharmaceutical products on the market today including PROZAC®, TAXOTERE®, GEMZAR®, CAMPTO®, LOVENOX®, GLIADEL®, SYNERCID®, NASACORT®, TILADE®, AZMACORT®, ESTALIS®, ZAGAM®, RILUTEK®, EVISTA®, REOPRO®, CESAMET®, LEVATOL®, HUMULIN®, ZYPREXA®, AXID®, PERMAX®, HUMATROPE®, DECABID®, DYNABAC®, PINDAC®, LORABID®, SUSTIVA®, VIASPAN®, DEFINITY® AND COUMADIN®.
``I have followed the progress of Introgen closely for a number of years,'' stated Dr. Talbott. ``I always believed INGN 201 possessed the characteristics to become a widely used cancer drug. I am eager to lead the global registration program for INGN 201. My goal in joining Introgen is simple; I want to register the world's first commercial gene therapy product, and I believe INGN 201 is that product.''<<
snip
Cheers, Tuck |
